{"id":"NCT01272193","sponsor":"Novo Nordisk A/S","briefTitle":"Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes","officialTitle":"A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes (BOOSTâ„¢: JAPAN)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-01","primaryCompletion":"2011-09","completion":"2011-09","firstPosted":"2011-01-07","resultsPosted":"2015-11-23","lastUpdate":"2017-03-17"},"enrollment":296,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"insulin degludec/insulin aspart","otherNames":[]},{"type":"DRUG","name":"insulin glargine","otherNames":[]}],"arms":[{"label":"IDegAsp OD","type":"EXPERIMENTAL"},{"label":"IGlar OD","type":"ACTIVE_COMPARATOR"}],"summary":"This trial is conducted in Japan. The aim of this trial is to investigate the efficacy and safety of NN5401 (insulin degludec/insulin aspart) with insulin glargine in subjects with type 2 diabetes in Japan. Depending on pre-trial oral anti-diabetic drugs (OADs), subjects continued at the same dose and dosing frequency.","primaryOutcome":{"measure":"Change in Glycosylated Haemoglobin (HbA1c)","timeFrame":"Week 0, Week 26","effectByArm":[{"arm":"IDegAsp OD","deltaMin":-1.35,"sd":0.86},{"arm":"IGlar OD","deltaMin":-1.22,"sd":0.98}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":50,"countries":["Japan"]},"refs":{"pmids":["23557077","35044568"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":147},"commonTop":["Nasopharyngitis","Diabetic retinopathy"]}}